| |
Centocor creates, acquires, develops and markets innovative, cost-effective biopharmaceuticals. Centocor products have revolutionized the management of coronary angioplasty, heart attack, Crohn's disease and rheumatoid arthritis.
Looking ahead, Centocor is committed to being the industry leader in biopharmaceutical research and development. The current R&D pipeline consists of 13 new indications for existing products, nine new molecular entities (NMEs) in development, and more than 25 innovative research projects directed at key molecular targets. Drug discovery and development efforts focus on the following therapeutic areas: cardiovascular/neurovascular/metabolic diseases, IMID (immune-mediated inflammatory disorders)/pulmonary, oncology and infectious diseases. Centocor is looking for novel approaches that address the pathology of these diseases.
Centocor has an impressive track record in developing and commercializing therapeutic products, such as REMICADE ® (infliximab), ReoPro ® (abciximab) and RETAVASE ® (reteplase), which together accounted for more than $2 billion in net sales in 2003. The world leader in monoclonal antibody production and technology, Centocor is an ideal match for innovative companies seeking a partner with proven global developmental and commercial expertise. Centocor is also interested in investing in novel, innovative ideas either to enable existing programs or to create new product development programs.
|
|
